Key facts
- It has raised $3.3M across 2 recorded rounds; the latest was Seed Round ($250K) in Jul 2025.
- Notable investors include Open Philanthropy Project, Georgia Research Alliance.
- Piezo Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Aug 2025 ($250K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Piezo Therapeutics
Funding rounds
2 roundsAbout Piezo Therapeutics
Operator of a drug delivery platform intended to replace lipid nanoparticles. The company's platform combines drug delivery technologies electric pulses and microneedles, allowing for the precise and controlled delivery of drugs to targeted areas of the body and thus improving the efficacy and safety of drugs and making them accessible to patients, enabling healthcare professionals to access improved RNA and DNA delivery and a wide range of nucleic acid medicines for vaccines, immunotherapies, therapeutic proteins, and gene therapies.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2022
- Employees
- 7
- Website
- piezotx.com/
- Ownership
- Privately Held (backing)
Piezo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Piezo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Piezo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.